Nezodia (Linagliptin)

Linagliptin, the active ingredient in Nezodia, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Nezodia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customer support includes technical assistance and documentation for import compliance.

Nezodia (linagliptin) belongs to the DPP‑4 inhibitor class used in the treatment of type 2 diabetes mellitus. - Type 2 diabetes mellitus (monotherapy): improves glycaemic control as an initial oral therapy. - Type 2 diabetes mellitus (combination therapy): enhances glucose lowering when added to metformin or other antidiabetic agents. - Adults with type 2 diabetes: reduces HbA1c levels when combined with diet and exercise.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Gastrointestinal discomfort: occasional nausea or abdominal pain. - Dizziness: occasional light‑headedness. - Fatigue: mild tiredness reported. - Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Acute kidney injury: sudden decline in renal function. - Bullous skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following precautions: - Renal impairment: monitor renal function regularly. - Hepatic disease: use with caution in patients with liver dysfunction. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Elderly patients: monitor for dehydration and orthostatic hypotension. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with several medicines. Review the following categories: Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Concomitant insulin or sulfonylureas: heightened risk of hypoglycaemia. Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin effectiveness. - Diuretics: may affect fluid balance and blood pressure. - Warfarin: monitor INR as changes in glycaemic control can influence anticoagulation.